According to ImmunoGen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -100.742. At the end of 2022 the company had a P/E ratio of -5.64.
Year | P/E ratio | Change |
---|---|---|
2022 | -5.64 | -49.11% |
2021 | -11.1 | -53.64% |
2020 | -23.9 | 231.92% |
2019 | -7.20 | 81.43% |
2018 | -3.97 | -36.88% |
2017 | -6.28 | 448.34% |
2016 | -1.15 | -88.43% |
2015 | -9.91 | 38.02% |
2014 | -7.18 | -81.9% |
2013 | -39.6 | 248.29% |
2012 | -11.4 | -13.49% |
2011 | -13.2 | 16.53% |
2010 | -11.3 | 9.19% |
2009 | -10.3 | 119.38% |
2008 | -4.71 | -55.7% |
2007 | -10.6 | -5.55% |
2006 | -11.3 | -20.94% |
2005 | -14.3 | -79.04% |
2004 | -68.0 | 452.08% |
2003 | -12.3 | 90.72% |
2002 | -6.46 | -91.43% |
2001 | -75.4 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.2 | -111.13% | ๐บ๐ธ USA |
Novartis NVS | 25.6 | -125.45% | ๐จ๐ญ Switzerland |
Pfizer PFE | 14.9 | -114.83% | ๐บ๐ธ USA |
Eli Lilly LLY | 143 | -242.27% | ๐บ๐ธ USA |
Amgen AMGN | 20.2 | -120.08% | ๐บ๐ธ USA |
Sanofi SNY | 15.6 | -115.46% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 13.4 | -113.31% | ๐บ๐ธ USA |
Seagen
SGEN | -57.0 | -43.38% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.